Malignant Pleural Effusions, NSCLC Stage IV
Conditions
Keywords
Malignant Pleural Effusions, NSCLC
Brief summary
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Detailed description
This study is consisted of two phase, Phase Ib and II: Phase 1b includes dose escalation phase and cohort expansion phase. In dose escalation phase, up to 4 dose-escalation cohorts will be sequentially enrolled with regular "3+3" design. DLTs will be evaluated during the first treatment cycle, which is 28 days. In cohort expansion phase, after the RP2D was identified, participants were enrolled in an open-ended manner. Participants were assigned to groups A(3 injections), B (4 injections)and C(6 injections) on a 1:1:1 basis to evaluate the dose frequency. Phase II:The dose and dosing frequency of M701 drug for the Phase II clinical trial were determined based on a combination of the tolerance1 and efficacy of M701 in the Phase Ib trial. Then the participants were randomly divided into two groups: the test group(M701) and the control group(cisplatin or pleural effusions suctions). The pleural effusions response (ORR) and Puncture Free Survival （PuFS）will be evaluated.
Interventions
DRUGM701 pleural infusion
M701 pleural infusion on Days 1,4,7 and 10.
PROCEDUREPleural drainage
Pleural effusion drainage via Ultra-sound guidance on Day 1.
DRUGCisplatin pleural infusion
Cisplatin pleural infusion (30-50mg/m2) on Day 1.
Sponsors
Wuhan YZY Biopharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
For Phase 2 study, the patients are enrolled into 2 arm parallelly.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged \>18 years and ≤ 75 years, male or female. 2. Histologically or cytologically confirmed advanced non-small cell lung cancer that has progressed after at least one line of systemic anti-tumor treatment (including subjects with local malignant pleural effusion progression or inadequately controlled). 3. Malignant pleural effusion requiring intrathoracic perfusion treatment (malignant pleural effusion should be diagnosed histologically or cytologically), with moderate or above amount of pleural effusion (the depth of pleural effusion by B-mode ultrasound in sitting position is ≥ 4 cm, and the actual drainage volume of pleural effusion is ≥ 500 mL), and the study physician judges that clinical intervention is required. 4. If the subject received latest systemic treatment regimen at least 1 course (at least 21 days for targeted therapy) and poorly controlled pleural effusion , then no washout interval is required. 5. Any toxicity from prior antineoplastic therapy should have recovered to Grade 0-1 as determined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V5.0, except alopecia, pigmentation, and Grade ≤ 2 neuropathy, hypothyroidism on hormone replacement therapy, or other adverse events that are confirmed to be chronic. 6. ECOG score (PS) of 0-1 (for subjects with inadequately controlled malignant pleural effusion of whom ECOG score is 2 can be enrolled). 7. An expected survival ≥ 12 weeks. 8.8.Organ functions must meet the following criteria: Hemogram (no transfusion of blood or blood products, no correction with granulocyte-colony stimulating factor (G-CSF) or other hematopoietic stimulating factors within 14 days before the first dose): absolute neutrophil count (ANC) ≥ 1.5 109/L, platelet (PLT) ≥ 100 109/L, and hemoglobin (HGB) ≥ 85 g/L; Hepatic function: total bilirubin (TBIL) ≤ 1.5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN (AST and ALT ≤ 5 × ULN in case of liver metastasis), serum albumin \> 28 g/L; Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN. 9.Understand and voluntarily sign the written informed consent form.
Exclusion criteria
1. Subjects with recurrent pleural effusion within 4 weeks after the last intrathoracic perfusion treatment and requiring clinical intervention. 2. Subjects who have received intrathoracic infusion of immune drugs, such as PD-1, PD-L1, CTLA-4, and other immune checkpoint inhibitors (excluding interleukins). 3. Subjects with malignant pleural effusion requiring clinical intervention on both sides, or those in whom adequate drainage of pleural effusion is not possible due to objective reasons (including loculated pleural effusion), or complicated with chylothorax, or with moderate or greater pericardial effusion, or pneumothorax. 4. Subjects with central nervous system (CNS) metastases resulting in clinical symptoms or requiring therapeutic intervention; patients with previously treated brain metastases can be enrolled if they are asymptomatic and have stable disease as indicated by imaging examination ≥ 4 weeks before the first dose and do not require corticosteroids or anticonvulsant therapy. 5. Subjects with known history of severe allergy to any ingredient of M701 or similar macromolecular antibody drugs. 6. Subjects with contraindications to thoracentesis. 7. Subjects who have undergone major surgery within 4 weeks before the first dose. 8. Subjects combined with active infection that have not been controlled to a clinically stable state within the previous 3 days before randomization. 9. Subjects who require long-term hormone or immunosuppressive therapy, such as active autoimmune diseases, maintenance therapy after organ transplantation, but patients with the following conditions are allowed to be screened: type I diabetes; hypothyroidism that can be controlled by replacement therapy only; skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, or alopecia). 10. Subjects with severe respiratory diseases or interstitial pneumonia, who are not suitable for enrollment as determined by the investigator. 11. Combined with severe cardiovascular disease, including cardiac insufficiency (New York Heart Association class III-IV), or acute cardiovascular event (such as acute myocardial infarction, acute cerebral infarction, angina pectoris unstable, hemorrhage brain, etc.) or pulmonary embolism within the past 6 months, or received a vascular stent implantation (such as coronary artery stent implantation, intracranial artery stent implantation, etc.) within the past 6 months; or experienced a new venous thrombotic disease such as lower extremity venous thrombosis has occurred within the past 1 month. 12. The mean corrected QT interval (QTcF) \> 450 ms (male) or \> 470 ms (female) in 3 electrocardiogram (ECG) examinations at screening (only those with QTcF \> 450 ms (male) or \> 470 ms (female) at the first ECG examination should be retested to obtain the mean corrected value of 3 retests); family or personal history of long or short QT syndrome; clinically significant history of arrhythmia, or implantation of defibrillation device for ventricular arrhythmia. 13. History of malignancy (other than the study tumor) within 3 years prior to the date of first dose of investigational drug (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other non-invasive diseases that are considered by the investigator and the sponsor to be cured with minimal risk of recurrence within 3 years). 14. Combined with active chronic hepatitis B (e.g., hepatitis B surface antigen \[HBsAg\]-positive and/or hepatitis B core antibody (HBcAb)-positive, with HBV-DNA quantification ≥1×10⁴ copies/mL or ≥2000 IU/mL), active hepatitis C (hepatitis C antibody-positive, and \[e.g., hepatitis C virus (HCV-RNA) higher than the analytical method\] antibody-positive, with HCV-RNA ≥ the lower limit of detection), \[,\] human immunodeficiency virus (HIV) antibody-positive or active syphilis, HIV antibody-positive infection (syphilis-specific antibody-positive and syphilis non-specific antibody-positive); 15. Pregnant or lactating women; men or women who plan to have children within 6 months after the end of this clinical study. 16. Subjects with a history of confirmed neurological or mental disorders who cannot cooperate with the treatment and follow the doctor's advice as judged by the investigator. 17. Other conditions that the investigator considers unsuitable for participating in this clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicities (DLTs) | From the time of the first dose (Day 1) until the forth dosing (Day 28) | Dose limiting toxicities during the first 28 days after the first administrations of study drug in each cohort. |
| Incidence of AEs | From the start of administration to the end of the study or 28 days after the administration is stopped | Incidence and severity of AEs, including but not limited to vital signs, physical examination, laboratory tests. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0. |
| Puncture-free survival (PuFS) | The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required or death, assessed up to 12 months after enrollment or randomization. | The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required (based on the time when puncture and drainage occur) or death, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve (AUC) of M701 | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. |
| Maximum observed concentration (Cmax) of M701 | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. |
| Minimum observed concentration (Cmin) of M701 | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | The endpoints for assessment of PK of M701 include serum concentrations of M701 at different timepoints after M701 administration. |
| Half-time (t1/2) of M701 | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | Half-time (t1/2) of M701 |
| Anti-drug antibodies(ADAs) titer | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | The immunogenicity of M701 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs). |
| Neutralizing antibody titer | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days) | The immunogenicity of M701 will be collected by testing the antibody titer of the neutralizing antibody. |
| Concentrations of tumor biomarker in pleural effusions | From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 56 days) | As tumor biomarkers, concentrations of CEA, CyFra21-1, SCC and NSE in malignant pleural effusions will be examined at Day 1 and Day10. |
| Expression level of EpCAM-positive cells in pleural effusions | From the time of first dosing (Day 1) until disease progression (up to 56 days) | The number and expression levels of EpCAM-positive cells in pleural effusions will be measured by pathological methods (including cytospin, immunohistochemical techniques, etc.) |
| Ratio of EpCAM-positive tumour cell/leucocyte | From the time of first dosing (Day 1) until disease progression (up to 56 days) | Ratio of EpCAM positive tumour cell/leucocyte in pleural effusions will be measured by FACS method. |
| Rate of with successful pleurodesis (4/8 weeks) | From the time of first dosing (Day 1) until disease progression (up to 56 days) | the rate of patients with successful pleurodesis at 4 weeks / 8 weeks |
| Puncture-free survival rate at 8 and 14 weeks after the first intrapleural dose. | 8 weeks and 14 weeks following the first dose . | Puncture-free survival rate at 8 and 14 weeks after the first intrapleural dose. |
| Pleural signs and symptoms | From the time of first dosing (Day 1) until disease progression (up to 56 days) | Using the Lister Quadruple Scale to record pleural effusions at 4 weeks/ 8 weeks. |
| Puncture-free survival (PuFS) | The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required or death, assessed up to 12 months after enrollment or randomization. | The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required (based on the time when puncture and drainage occur) or death, whichever occurs first. |
| Time to Next Puncture (TTNP) | The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required, assessed up to 12 months after enrollment or randomization. | Defined to be the period from the end of the treatment (based on the time when the thoracic drainage tube is removed, the same as the starting time point of PuFS) to the time when the subject requires another thoracic puncture for drainage. |
| Quality of life score | From Day 1 (enrollment or randomization) to the end of the study , up to 1 year. | Evaluated according to the EORTC quality of life scale QLQ-C30 (V3.0) and scale QLQ-LC13 (see Appendix 3 for details) |
Countries
China
Contacts
CONTACTShaoYi Huang
CONTACTLi Huang
PRINCIPAL_INVESTIGATORYiping Zhang
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
PRINCIPAL_INVESTIGATORZhengbo Song
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Outcome results
None listed